Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects
Information source: Eye Therapies, LLC
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ocular Redness
Intervention: Placebo (Drug); Brimonidine tartrate 0.025% (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Eye Therapies, LLC
Summary
The purpose of this study is to evaluate the safety and efficacy of brimonidine tartrate
0. 025% ophthalmic solution used four times daily in a population of adult and geriatric
subjects
Clinical Details
Official title: A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Ocular redness
Secondary outcome: Ocular Redness
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Be at least 40 years of age
- Must have normal ocular health
- Must have history of redness relief drop use or desire to use
Exclusion Criteria:
- Must not have any ocular/systemic health problems
- Must agree to avoid disallowed medications
Locations and Contacts
Ora, Inc., Andover, Massachusetts 01810, United States
Additional Information
Starting date: August 2012
Last updated: July 28, 2014
|
